Compare 10X Genomics Inc (TXG) vs Wynn Resorts, Limited (WYNN) Price & Performance

10x Genomics (TXG) trades at $77.28, up 1.55% on the day, with a bearish technical signal from moving averages. The company shows improving fundamentals with revenue of $642.82M in 2025 and a reduced net loss of -$43.54M, while recent news highlights strong demand for its Atera spatial biology platform and a patent victory. Positive earnings beats in recent quarters contrast with a high EV/EBITDA of 249.22, indicating significant growth expectations are priced in.

The outlook is mixed; analyst consensus is neutral with a $74.30 price target slightly below the current price, yet operational cash flow turned strongly positive in 2025. Key risks include persistent net losses, high valuation multiples, and execution on new product launches. The stock's near-term direction hinges on Atera's commercial success and achieving profitability.

Wynn Resorts (WYNN) trades at $75.29, up 0.43% on the day, with a bearish technical signal from moving averages despite a neutral oscillator stance. The company reported a Q2 2026 earnings beat with EPS of $1.24 versus $0.992 expected, driven by Macau strength, though U.S. margins face pressure. Revenue for 2025 was $7.14B with a net income margin of 4.58%, while the balance sheet shows high leverage with total liabilities of $13.95B against negative shareholder equity. Recent news highlights institutional buying interest and a new $900 million senior notes offering.

The outlook is mixed: strong analyst consensus (64% buy ratings) and a $132.36 price target suggest upside, but high debt, rising capex for UAE projects, and volatile Macau performance pose significant risks. Investors should weigh growth potential against financial leverage and regional economic sensitivities.